ArticlePLOS global public health2025
Access to essential medicines for noncommunicable diseases during conflicts: The case cardiovascular diseases, diabetes and epilepsy in Northern Syria.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Medication access barriers and perceived health consequences in post-war Syria: a cross-sectional study in Homs.Global health action · 2026Article
- Epidemiological trends of type 2 diabetes in Middle East and North Africa, 1990-2023: global burden of disease data analysis.International journal of public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Access to essential medicines is a critical component of healthcare. Conflicts severely disrupt pharmaceutical supply chains. This study examines the availability and prices of essential noncommunicable diseases (NCDs) medicines in Northern Syria, and explores the underlying factors contributing to medicine shortages and price variability. We applied a mixed-methods approach, combining a cross-sectional quantitative survey based on the World Health Organization/Health Action International (WHO/HAI) methodology with qualitative interviews. Medicine availability and price data were collected from public healthcare facilities and private pharmacies across Northeast and Northwest Syria. Availability was calculated as the percentage of facilities with the medicine in stock and categorized into four levels. Prices were reported using median price ratios. Qualitative data were collected from retailer pharmacists, representatives from non-governmental organizations (NGOs), and personnel working in medicine warehouses and wholesale distribution. Thematic content analysis was employed to analyze the qualitative data. The findings indicate low medicine availability, falling well below WHO targets. The mean availability was 45.5%. Of 28 medicines surveyed, 11 had somewhat high availability (50%-80%), 12 had low availability (30%-49%), and 5 had very low availability (<30%). Epilepsy medicines had the lowest availability, highlighting a particularly neglected area of care. Qualitative report suggested that the observed price variations were largely driven by the geopolitical tension, supply chain disruptions, and the absence of effective regulatory mechanisms. The conflict has caused or exacerbated shortages through the destruction of infrastructure, trade restrictions, and economic instability. Additionally, concerns over the quality of medicines were frequently reported. This study highlights challenges in accessing essential medicines in Northern Syria but also reveals that medicine supply systems, although disrupted, continue to operate through alternative and informal channels. Moving forward, efforts must prioritize coherent, context-sensitive policies that build on existing structures and human resources to rebuild a well-regulated and equitable system.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.